Polyphor stays above water after Sfr165m IPO

By Aidan Gregory
15 May 2018

Swiss biopharmaceutical company Polyphor has bucked the trend of recent European IPOs by pricing its IPO at Sfr38, in the top half of the initial Sfr30 to Sfr40 range, and increasing the size of the deal.

Deutsche Bank and UBS were global coordinators.

At the final offer price, Polyphor is valued at Sfr420m. It began trading on the SIX Swiss Exchange on Tuesday May 15. The final size of the all primary IPO was Sfr165m, including the greenshoe. 

The stock opened at Sfr40 but ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.